AL-S Pharma AG today announced positive topline Phase 2 results for AP-101, a first-in-class investigational antibody targeting misfolded SOD1, a pathological hallmark of amyotrophic lateral sclerosis (ALS).
Key Findings
- Primary endpoint met: AP-101 demonstrated favorable safety and tolerability.
- Clinically meaningful signals:
- Improvements in survival and non-invasive ventilation outcomes.
- Stabilization of disease staging and neurofilament biomarkers.
- Broad relevance: First Phase 2 study of a SOD1-targeted therapy in both sporadic ALS and SOD1-mutation ALS.
- Next steps: Results will be presented at upcoming ALS conferences and submitted to regulatory authorities later this year
Expert Commentary
“These Phase 2 results are an important step toward developing a disease-modifying therapy for ALS. We are grateful to participants, families, and global ALS experts who made this trial possible.”
- Michael Salzmann, PhD, CEO, AL-S Pharma.
“This is the first controlled study testing a SOD1-targeted therapy across both sporadic and genetic ALS. The findings support misfolded SOD1 as a general disease driver in ALS.”
- Prof. Peter Andersen, Umea University, principal investigator.
Upcoming Presentations
- 36th International Symposium on ALS/MND
- Top-line results of the Phase 2 proof-of-concept study of AP-101
- Presenter: Prof. Dr. Angela Genge (McGill University, Canada)
- Date: December 5, 2025 | Oral session - 2025 Annual NEALS Meeting
- Baseline characteristics and analysis of misfolded SOD1 target levels in Phase 2
- Presenter: Prof. Dr. Angela Genge
- Date: October 2025 | Poster presentation
About AP-101
- Mechanism: Human monoclonal antibody targeting misfolded SOD1, aiming to halt its spread in cerebrospinal fluid and spinal cord.
- Indications: Sporadic ALS and SOD1-mutation ALS.
- Regulatory status: Orphan Drug Designation granted by FDA, EMA, and Swissmedic.
- Origin: Discovered using Neurimmune’s Reverse Translational Medicine™ (RTM™) platform.
About AL-S Pharma
- Founded: 2016 by Neurimmune and TVM Capital Life Science.
- Focus: Single-asset biotech advancing AP-101.
- Funding: Backed by TVM Life Science Innovation I and Neurimmune.
- Leadership: Includes experts from McGill University, Neurimmune, and TVM Capital.
Why It Matters
- ALS remains a fatal neurodegenerative disease with very limited treatment options.
- Targeting misfolded SOD1 could address a shared disease driver across both genetic and sporadic ALS.
- Phase 2 data position AP-101 as a potential disease-modifying therapy, with regulatory engagement planned in 2025.
